Abstract：Objective To evaluation therapeutic effect and adverse reaction of siggio capsules for palliative chemotherapy in the patients of advanced tumor.  Methods A total of 90 patients with advanced cancer who received palliative chemotherapy in our hospital from August 2019 to August 2021 were selected and divided into reference group and study group according to the treatment regimen, with 45 patients in each group. The patients in reference group were treated with oxaliplatin, and the study group were additionally treated with siggio capsules on the basis of the reference group. The total treatment effective rate, disease control rate, quality of life score, serum tumor marker levels and incidence of adverse reactions were compared between the two groups.  Results The total effective rate and disease control rate of the study group were higher than those of the reference group, and the differences between the two groups were statistically significant（χ2＝4.630, 11.791, all P＜0.05）; the posttreatment quality of life scores and tumor marker levels of the study group were better than those of the reference group, and the differences between the two groups were statistically significant （t＝6.596, 8.914, 6.583, 11.235, 9.587, 7.796, 5.240, all P＜0.05）; while the differences were not statistically significant when comparing the incidence of adverse reactions in both groups（χ2＝0.421, 0.830, 0.212, 0.963, all P＞0.05）.  Conclusion The application of siggio capsules in the palliative chemotherapy treatment of patients with advanced tumors is more conducive to improving the therapeutic effect, reducing the level of tumor markers, and improving the quality of life of patients, which is worth promoting.